Oculus Completes Patient Treatment in Phase II Diabetic Foot Ulcer Trial
Posted on: Friday, 4 January 2008, 09:00 CST
Oculus Innovative Sciences has completed patient treatment and follow-up in a randomized and controlled Phase II clinical trial evaluating its Microcyn technology in the treatment of mildly infected diabetic foot ulcers. The final patient evaluation occurred on December 24, 2007.
The Phase II randomized, controlled open-label study enrolled a total of 67 patients with mildly infected diabetic foot ulcers at 15 US sites. Three treatment arms were evaluated: 1) topical Microcyn alone 2) topical Microcyn in combination with oral levofloxacin and 3) topical saline in combination with oral levofloxacin. The company expects to provide preliminary top line Phase II clinical trial results in first quarter of 2008.
Hoji Alimi, chairman and CEO of Oculus Innovative Sciences, said: "Our intent is to use the various data points in the Phase II trial as the foundation for moving the company's clinical program forward."
Source: Datamonitor
Related Articles
- Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
- Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
- Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
- Hana Biosciences Commences Phase 1 Clinical Trial of Topical Menadione for Treatment and/or Prevention of EGFR Inhibitor-Associated Skin Rash
- Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
- Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
- NanoBio(R) Corporation Initiates Phase 2 Clinical Trial for Treatment of Onychomycosis
- Vyteris Announces Positive Results in Two Phase I Clinical Trials for Treatment of Infertility; Data Indicate Actyve(TM) Transdermal Drug Delivery Achieves Therapeutic Levels Of A Peptide Used For Treatment Of Infertility In Humans
- Molecular Insight Pharmaceuticals, Inc. Initiates Azedra(TM) Phase 1 Clinical Trial for Treatment of Neuroendocrine Cancer; Orphan Drug Targeted Radiotherapeutic Candidate Also Receives Fast Track Status
- Metabolex Reports Positive Phase 1 Clinical Trial for Treatment of Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds